Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis
Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis. // Journal of Surgical Research. – URL: https://www.sciencedirect.com/science/article/pii/S0022480426005731?dgcid=rss_sd_all
Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis. Journal of Surgical Research. https://www.sciencedirect.com/science/article/pii/S0022480426005731?dgcid=rss_sd_all
“Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis.” Journal of Surgical Research.
@article{article55636,
title = {Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis},
journal = {Journal of Surgical Research},
url = {https://www.sciencedirect.com/science/article/pii/S0022480426005731?dgcid=rss_sd_all}
}
ABSTRACT Objectives The aim of this study was to determine whether certain cephalometric findings can predict the future need for orthognathic surgery (OS) in cleft lip (CL), cleft palate (CP), unilateral cleft lip and palate (UCLP),...